Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.
leia mais em NPR
No comments:
Post a Comment